JP6612881B2 - 新規なアザベンゾイミダゾール誘導体 - Google Patents

新規なアザベンゾイミダゾール誘導体 Download PDF

Info

Publication number
JP6612881B2
JP6612881B2 JP2017537449A JP2017537449A JP6612881B2 JP 6612881 B2 JP6612881 B2 JP 6612881B2 JP 2017537449 A JP2017537449 A JP 2017537449A JP 2017537449 A JP2017537449 A JP 2017537449A JP 6612881 B2 JP6612881 B2 JP 6612881B2
Authority
JP
Japan
Prior art keywords
group
imidazo
hexahydrofuro
oxy
pyridin
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2017537449A
Other languages
English (en)
Japanese (ja)
Other versions
JP2018502135A5 (enExample
JP2018502135A (ja
Inventor
フランク ヒンメルスバッハ
エルケ ラングコップ
Original Assignee
ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング filed Critical ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング
Publication of JP2018502135A publication Critical patent/JP2018502135A/ja
Publication of JP2018502135A5 publication Critical patent/JP2018502135A5/ja
Application granted granted Critical
Publication of JP6612881B2 publication Critical patent/JP6612881B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Diabetes (AREA)
  • Epidemiology (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Endocrinology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Child & Adolescent Psychology (AREA)
  • Emergency Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
JP2017537449A 2015-01-16 2016-01-13 新規なアザベンゾイミダゾール誘導体 Active JP6612881B2 (ja)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
EP15151419.7 2015-01-16
EP15151419 2015-01-16
EP15167116 2015-05-11
EP15167116.1 2015-05-11
PCT/EP2016/050557 WO2016113299A1 (en) 2015-01-16 2016-01-13 New azabenzimidazole derivatives

Publications (3)

Publication Number Publication Date
JP2018502135A JP2018502135A (ja) 2018-01-25
JP2018502135A5 JP2018502135A5 (enExample) 2019-02-28
JP6612881B2 true JP6612881B2 (ja) 2019-11-27

Family

ID=55129871

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2017537449A Active JP6612881B2 (ja) 2015-01-16 2016-01-13 新規なアザベンゾイミダゾール誘導体

Country Status (4)

Country Link
US (1) US10053471B2 (enExample)
EP (1) EP3245212B1 (enExample)
JP (1) JP6612881B2 (enExample)
WO (1) WO2016113299A1 (enExample)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2016068099A1 (ja) 2014-10-28 2016-05-06 塩野義製薬株式会社 Ａｍｐｋ活性化作用を有する複素環誘導体
CA3014858A1 (en) 2016-02-26 2017-08-31 Shionogi & Co., Ltd. 5-phenylazaindole derivative having ampk-activating activity
CA3024090A1 (en) * 2016-05-20 2017-11-23 Shionogi & Co., Ltd. 5-substituted benzimidazole and 5-substituted azabenzimidazole derivative both having ampk activation effect
CN106278970A (zh) * 2016-08-09 2017-01-04 孙冉 一种二芳基亚砜胺类化合物的合成方法
UY39222A (es) 2020-05-19 2021-11-30 Kallyope Inc Activadores de la ampk
AU2021297323A1 (en) 2020-06-26 2023-02-16 Kallyope, Inc. AMPK activators

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BR122021002201A8 (pt) * 2011-02-25 2023-04-11 Merck Sharp & Dohme Composto, composição, uso de um composto, e, método de tratamento de um distúrbio, condição ou doença
WO2014069426A1 (ja) * 2012-10-31 2014-05-08 塩野義製薬株式会社 Ａｍｐｋ活性化作用を有するベンズイミダゾールおよびアザベンズイミダゾール誘導体
CN105377857B (zh) * 2013-07-17 2018-04-10 勃林格殷格翰国际有限公司 新颖氮杂苯并咪唑衍生物

Also Published As

Publication number Publication date
WO2016113299A1 (en) 2016-07-21
US10053471B2 (en) 2018-08-21
EP3245212A1 (en) 2017-11-22
US20180002349A1 (en) 2018-01-04
JP2018502135A (ja) 2018-01-25
EP3245212B1 (en) 2019-03-13

Similar Documents

Publication Publication Date Title
JP6612881B2 (ja) 新規なアザベンゾイミダゾール誘導体
JP6588966B2 (ja) Ａｍｐタンパク質キナーゼ作動薬としてのアザベンゾイミダゾール誘導体
JP6491656B2 (ja) 新規アザベンズイミダゾール誘導体
EP2953681B1 (en) New indanyloxydihydrobenzofuranylacetic acids
JP6612880B2 (ja) Ａｍｐ活性化タンパク質キナーゼのアゴニストとしての新規アザベンゾイミダゾール誘導体
JP6474804B2 (ja) アザベンゾイミダゾール誘導体
EP2847196B1 (en) New 2,3-dihydro-furo[2,3-c]pyridines, their use as modulators of the g-protein-coupled receptor gpr119 and pharmaceutical compositions comprising them
WO2016001224A1 (en) Novel activators of amp-activated protein kinases

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20190115

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20190115

TRDD Decision of grant or rejection written
A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20191003

A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20191021

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20191031

R150 Certificate of patent or registration of utility model

Ref document number: 6612881

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250